Short interest for Aurora Cannabis gives investors a sense of the degree to which investors are betting on the decline of Aurora Cannabis's stock. Short interest data is updated every two weeks.

Aurora Cannabis Stock (NASDAQ:ACB), Short Interest Report

Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.

Hand,Holding,Cannabis,Bud,Agains,Trail,And,Blue,Sky,Landscape

Cannabis

News

Eurozone

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

TLRY

Cannabis Shops Could Launch This Year In Germany For &#39;Scientific Purposes,&#39; Here&#39;s Why UK&#39;s Medical Marijuana Sales Are Soaring

auroracannabis

Technicals

Markets

Trading Ideas

Aurora Cannabis&#39; &#34;Golden Cross&#34; pattern is a bullish signal and comes as marijuana market conditions improve across various states

Aurora Cannabis: Medical Market In Focus, Golden Cross Suggests Stock Uptrend Ahead Of Q1 Earnings

AI Generated Image 

Analyst Color

Market Summary

Analyst Ratings

General

Following the recent move on the part of the DEA toward 

Post Cannabis Rescheduling: What&#39;s Next For Marijuana Giants? Potential $1.1B Cash Flow Boost From IRS 280E Removal

Aurora Cannabis Inc

Ace Global Business Acquisition Limited - Ordinary Shares

Ace Global Business Acquisition Ltd

Ace Global Business Acquisition Limited - Unit

Ace Global Business Acquisition Limited - Warrant

ALBINA COMMUNITY BNCRP by Albina Community Bancorp

Albina Community Bancorp

Annabidiol Corp

ARCO BIOMEDICAL CO LTD by Acro Biomedical Co., Ltd.

Acro Biomedical Co Ltd

Aurora Cannabis Inc Warrants (31/05/2025)

<p>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.78) by 110.26 percent.  The company reported quarterly sales of $11.09 million which beat the analyst consensus estimate of $5.90 million by 87.99 percent.  This is a 69.73 percent decrease over sales of $36.63 million the same period last year.</p>


Earnings

Earnings Beats

MTEM

Molecular Templates Q1 2024 GAAP EPS $0.08 Beats $(0.78) Estimate, Sales $11.09M Beat $5.90M Estimate

<p>Sadot Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 75 percent increase over losses of $(0.04) per share from the same period last year.</p>


SDOT

Sadot Group Q1 2024 GAAP EPS $(0.01) Beats $(0.05) Estimate

<p><strong>Microsoft Corp. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) <a href="https://news.xbox.com/en-us/2024/05/14/xbox-game-pass-may-2024-wave-2/">unveiled</a> the second wave of Xbox Game Pass additions for May 2024, featuring a variety of games <a href="https://www.benzinga.com/24/05/38711579/lords-of-the-fallen-sniper-ghost-warrior-contracts-2-to-join-microsofts-xbox-game-pass">spanning different genres. </a></p>
<p>Highlighting this lineup is the highly anticipated Hellblade 2 from Ninja Theory, along with other exciting titles that cater to diverse gaming preferences. From puzzle adventures and sports games to dark fantasy action RPGs, there&#8217;s something for every gamer this month.</p>
<p><em>See Also: <a href="https://www.benzinga.com/general/gaming/24/05/38791690/xbox-exec-sarah-bond-addresses-microsofts-studio-closures-its-always-extraordinarily-hard-to-make-">Xbox Exec Sarah Bond Addresses Microsoft&#8217;s Studio Closures: &#8216;It&#8217;s Always Extraordinarily Hard To Make Decisions Like That&#8217;</a></em></p>
<p>Xbox Game Pass continues to expand its offerings, ensuring subscribers have access to new and engaging content. This month also includes some day-one launches, giving gamers immediate access to the latest titles. </p>
<p>As new games join the service, a few will be leaving, offering members the chance to purchase them at a discount before they are removed.</p>
<h3 class="wp-block-heading">Games Joining Xbox Game Pass</h3>
<ul>
<li><strong>Chants of Sennaar (Cloud, Console, and PC) – May 15</strong>
<ul>
<li>A puzzle adventure game exploring language and communication through intricate challenges.</li>
</ul>
</li>
<li><strong>EA Sports NHL 24 (Cloud) EA Play – May 16</strong>
<ul>
<li>Experience the latest in EA&#8217;s hockey franchise via Xbox Cloud Gaming.</li>
</ul>
</li>
<li><strong>Immortals of Aveum (Cloud, PC, and Xbox Series X&#x7C;S) EA Play – May 16</strong>
<ul>
<li>A first-person magic shooter with a solo campaign and fast-paced combat.</li>
</ul>
</li>
<li><strong>Senua's Saga: Hellblade II (Cloud, PC, and Xbox Series X&#x7C;S) – May 21</strong>
<ul>
<li>A dark and immersive action-adventure game continuing Senua&#8217;s journey.</li>
</ul>
</li>
<li><strong>Galacticare (Cloud, PC, Xbox Series X&#x7C;S) – May 23</strong>
<ul>
<li>Manage an interstellar healthcare company and save the galaxy in story or sandbox mode.</li>
</ul>
</li>
<li><strong>Hauntii (Cloud, Console, and PC) – May 23</strong>
<ul>
<li>Play as a ghost on a puzzle-solving quest in a captivating adventure.</li>
</ul>
</li>
<li><strong>Moving Out 2 (Cloud, Console, and PC) – May 28</strong>
<ul>
<li>A colorful and chaotic co-op moving simulator with humorous gameplay.</li>
</ul>
</li>
<li><strong>Humanity (Cloud, Console, and PC) – May 30</strong>
<ul>
<li>A modern reimagining of Lemmings with a powerful level editor and unique puzzles.</li>
</ul>
</li>
<li><strong>Lords of the Fallen (Cloud, PC, and Xbox Series X&#x7C;S) – May 30</strong>
<ul>
<li>A dark fantasy action-RPG featuring a dual-realities premise and intense combat.</li>
</ul>
</li>
<li><strong>Firework (PC) – June 4</strong>
<ul>
<li>A horror puzzle game challenging players with eerie and mind-bending puzzles.</li>
</ul>
</li>
<li><strong>Rolling Hills (Cloud, Console, and PC) – June 4</strong>
<ul>
<li>A day-one launch featuring life simulation gameplay in a serene environment.</li>
</ul>
</li>
</ul>
<h3 class="wp-block-heading">Games Leaving Xbox Game Pass on May 31</h3>
<ul>
<li><strong>Chicory: A Colorful Tale (Cloud, Console, and PC)</strong></li>
<li><strong>Farworld Pioneers (Cloud, Console, and PC)</strong></li>
<li><strong>JoJo's Bizarre Adventure: All-Star Battle (Cloud, Console, and PC)</strong></li>
<li><strong>Pac-man Museum Plus (Cloud, Console, and PC)</strong></li>
<li><strong>Little Witch in the Woods (Cloud, Console, and PC)</strong></li>
<li><strong>Railway Empire II (Cloud, Console, and PC)</strong></li>
</ul>
<p><em>Read Next: <a href="https://www.benzinga.com/general/gaming/24/05/38741114/will-call-of-duty-join-xbox-game-pass-internal-debates-at-microsoft-potential-price-hike-report">Will Call Of Duty Join Xbox Game Pass? &#8216;Internal Debates&#8217; At Microsoft, Potential Price Hike: Report</a></em></p>
<p><em>Image credits: Shutterstock.</em></p>


Gaming

MSFT

Xbox Game Pass May 2024 Wave 2: Hellblade 2 And More New Titles

<p>Elevai Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) reported quarterly losses of $(0.08) per share. This is a 27.03 percent increase over losses of $(0.11) per share from the same period last year. The company reported $614.56 thousand in sales this quarter. This is a 330.31 percent increase over sales of $142.82 thousand the same period last year.</p>


ELAB

Elevai Labs Q1 EPS $(0.081) Up From $(0.111) YoY, Sales $614.56K Up From $142.82K YoY

Financing

CNTG

CENTOGENE Entered Into Agrements With Lifera; Provides ~$20M Funding

Hedge Funds

13F Shows Soros Fund Management LLC Decreased Stake in Novo-Nordisk A S by 757.21K Shares, or -49%, to 797.62K Shares, Valued at $102.41M

AMZN

13F Shows Soros Fund Management LLC Increased Stake in Amazon Com Inc by 280.71K Shares, or +17%, to 1.92M Shares, Valued at $107.90M

GOOG

GOOGL

13F Shows Soros Fund Management LLC Increased Stake in Alphabet Inc by 271.52K Shares, or +22%, to 1.49M Shares, Valued at $224.98M

<p>XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) reported quarterly losses of $(0.60) per share. This is a 57.14 percent increase over losses of $(1.40) per share from the same period last year. The company reported $8.73 million in sales this quarter. This is a 23.55 percent increase over sales of $7.06 million the same period last year.</p>


XWEL

XWELL Q1 EPS $(0.60) Up From $(1.40) YoY, Sales $8.73M Up From $7.06M YoY

<p><strong>Chubb Limited </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) shares are trading higher after the bell Wednesday following an SEC filing showed <strong>Berkshire Hathaway </strong>purchased <a href="https://www.benzinga.com/news/24/05/38582096/chubb-braces-for-record-shipping-insurance-loss-after-350m-payout-for-baltimore-bridge-collapse">shares of the stock.</a></p>
<h1 class="wp-block-heading"><strong>The Details</strong></h1>
<p>The 13F <a href="https://www.sec.gov/Archives/edgar/data/1067983/000095012324005622/xslForm13F_X02/32398.xml">filing</a> revealed Berkshire Hathaway had purchased 25.92 million Chubb shares valued at over $6.717 billion. </p>
<p>Chubb is one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal property and casualty insurance, reinsurance and life insurance.</p>
<p><em>Related News: </em><a href="https://www.benzinga.com/news/24/05/38819804/whats-going-on-with-nikolas-stock"><em>What&#8217;s Going On With Nikola&#8217;s Stock?</em></a></p>
<h1 class="wp-block-heading"><strong>Is CB A Good Stock To Buy?</strong></h1>
<p>Wall Street analysts view Chubb on the whole as a Outperform, given the history of coverage over the past three months. <strong>Michael Ward</strong> from Citigroup is the most optimistic, expecting a 15.55% rise in the stock in the coming year.</p>
<p>But looking at how the market as a whole thinks of the stock, reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, Chubb rose 0.72%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 12.43% over the past year.</p>
<p>A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real-time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.</p>
<p><strong>CB Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Chubb shares are up 5.15% after-hours at $266 at the time of publication Wednesday.</p>
<p><em>Image: Shutterstock</em></p>


After-Hours Center

Movers

Insurance

Chubb Stock Climbs After Berkshire Hathaway Purchases Shares

DJt Trump Media & Technology Group Corp Files Non Timely 10-Q With SEC; Due To Timing Of Appointment Of SMC, Unable Without Unreasonable Effort And Expense To Complete Review Of Financials

<p>Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year.  The company reported quarterly sales of $2.829 million which beat the analyst consensus estimate of $2.405 million by 17.63 percent.  This is a 35.29 percent increase over sales of $2.091 million the same period last year.</p>


BRFH

Barfresh Food Group Q1 2024 GAAP EPS $(0.03) Beats $(0.04) Estimate, Sales $2.829M Beat $2.405M Estimate

<p>Retractable Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RVP#AMEX">RVP</a>) reported quarterly earnings of $0.01 per share. This is a 66.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported $7.60 million in sales this quarter. This is a 30.92 percent decrease over sales of $11.00 million the same period last year.</p>


Retractable Technologies Q1 EPS $0.01 Down From $0.03 YoY, Sales $7.60M Down From $11.00M YoY

<p>IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) reported quarterly losses of $(0.20) per share. This is a 11.11 percent decrease over losses of $(0.18) per share from the same period last year.  The company reported quarterly sales of $6.953 million which missed the analyst consensus estimate of $9.000 million by 22.74 percent.  This is a 20.43 percent decrease over sales of $8.738 million the same period last year.</p>


Earnings Misses

IZEA

IZEA Worldwide Q1 2024 GAAP EPS $(0.20) Down From $(0.18) YoY, Sales $6.953M Miss $9.000M Estimate

Visa Unveils New Products And Services At The Annual Visa Payments Forum In San Francisco

<p>Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) reported quarterly losses of $(2.99) per share.</p>


Sable Offshore Q1 2024 EPS $(2.99)

<p>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.54) by 53.7 percent.  The company reported quarterly sales of $119.035 million which missed the analyst consensus estimate of $129.778 million by 8.28 percent.  This is a 21.41 percent decrease over sales of $151.463 million the same period last year.</p>


NOTV

Inotiv Q2 2024 Adj EPS $(0.83) Misses $(0.54) Estimate, Sales $119.035M Miss $129.778M Estimate

<p>In its May 15, 2024 decision, the Court awarded the Columbia stockholders damages of US$398.4 million and has allocated responsibility for that award in the amount of 50 per cent to the former Columbia CEO and CFO, collectively, and 50 per cent to TC Energy. TC Energy continues to disagree with many of the Court's findings and believes the Court's ruling departs from established Delaware law. TC Energy's allocated share of the damages is US$199.2 million, plus an estimated US$179.5 million in pre- and post-judgment interest.</p>


Legal

TC Energy To Appeal Court Rulings Related To 2016 Columbia Pipeline Acquisition; Court Awarded Columbia Stakeholders Damages Of $398.4M

<p>Eyes are fixed on retail giants <strong>Walmart Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), <strong>Lowe&#8217;s Companies Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), <strong>Target Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), <strong>Costco Wholesale Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) and others who are set to set to release earnings this spring. Foot traffic data could provide a glimpse into the <a href="https://www.benzinga.com/topic/retail">sector&#8217;s upcoming performance</a>.</p>
<p><strong>Walmart and Sam&#8217;s Club Foot Traffic:</strong> <a href="https://www.placer.ai/blog/walmart-target-and-wholesale-clubs-continue-to-thrive">According</a> to <strong>Placer.ai</strong>, visits at Walmart were up 3.9% year-over-year, and at subsidiary Sam's Club they were up 6.1%. Walmart's year-over-year visits fell 2.7% in April, rose 7.7% in March and rose 4.4% in February while Sam's Club's visits were up 1.9% in April, up 8.2% in March and up 6.9% in February. The company posted solid growth in Minnesota, Wyoming, North Dakota and South Dakota.</p>
<p>Walmart will <a href="https://www.benzinga.com/earnings">release</a> first-quarter earnings on May 16.</p>
<p><strong>Lowe&#8217;s Foot Traffic:</strong> Lowe's visits during the first quarter were <a href="https://www.placer.ai/blog/home-improvement-and-decor-check-in">down</a> 4% year-over-year, up 0.2% in April, down 1.1% in March and down 2.8% in February. Competitor <strong>Home Depot Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), which already released earnings on May 14, reported visits down 1.1% year-over-year during the first quarter.</p>
<p>Lowe&#8217;s will <a href="https://www.benzinga.com/earnings">report</a> first-quarter earnings on May 21.</p>
<p><em>Now Read: <a href="https://www.benzinga.com/general/entrepreneurship/24/05/38847195/want-to-start-a-business-now-might-be-the-best-time-for-startups-in-decades">Want To Start A Business? Now Might Be The Best Time For Startups In Decades</a></em></p>
<p><strong>Target Foot Traffic:</strong> Visits in the first quarter at Target were up 3.5% year-over-year. Visits climbed 1.4% in April, 6.3% in March and 5.3% in February.</p>
<p>Target will <a href="https://www.benzinga.com/earnings">report</a> first-quarter earnings on May 22.</p>
<p><strong>Costco Foot Traffic:</strong> Costco saw the biggest gains in foot traffic in the first quarter. Visits soared 8.9% year-over-year and were up 9.2% in April, 10.5% in March and 10.9% in February.</p>
<p>Costco will report first-quarter earnings on May 30.</p>
<p><em>Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38850154/economists-react-to-inflation-retail-sales-the-soft-landing-narrative-is-still-a-po">Economists React To Inflation, Retail Sales: &#8216;The Soft Landing Narrative Is Still A Possibility But Not A Guarantee&#8217;</a></em></p>
<p><em>Photo: Walmart via Shutterstock</em></p>


Equities

COST

Walmart, Lowe's, Target, Costco Foot Traffic Data Gives Hints About Retail Performance Ahead Of Earnings

<p><strong>Rudy Giuliani</strong> took part in an alleged scheme to overturn the 2020 <a href="https://www.benzinga.com/news/24/04/38420233/trump-allies-giuliani-meadows-indicted-by-arizona-grand-jury-for-alleged-2020-election-subversion-ex">presidential election results in Arizona</a>.</p>
<p>Prosecutors can&#8217;t find the former New York City mayor to serve him legal papers.</p>
<p><strong>What Happened</strong>: A group of ex-President <strong>Donald Trump</strong>'s allies were indicted last month in Arizona. Prosecutors also charged 11 individuals who acted as fake GOP electors.</p>
<p>Giuliani, who <a href="https://www.benzinga.com/news/23/12/36350376/rudy-giuliani-files-for-bankruptcy-in-wake-of-146-million-judgment">went bankrupt in December</a>, is the only defendant prosecutors have been unable to serve with a summons.</p>
<p>Calls to the Arizona attorney general's office were not immediately returned. </p>
<p>A team of prosecutors and investigators working for Arizona Attorney General <strong>Kris Mayes</strong>, a Democrat, has made multiple attempts to locate Giuliani, CNN <a href="https://www.cnn.com/2024/05/14/politics/arizona-officials-giuliani-indictment-2020/index.html">reported</a>.</p>
<p>Agents working with the attorney general's office traveled to New York City to hand-deliver the notice to Giuliani. They were not allowed to service the documents at the front desk where Giuliani lives, according <a href="https://www.washingtonpost.com/national-security/2024/05/14/rudy-giuliani-arizona-charges/">to</a> the Washington Post.</p>
<p>Giuliani lost his radio show at New York City&#8217;s WABC affiliate last week. He quickly relaunched &#8220;The Rudy Giuliani Show&#8221; on YouTube and is believed to be livestreaming from his apartment.</p>
<p><em>See Also: <a href="https://www.benzinga.com/news/24/05/38836381/anthony-scaramucci-says-trump-may-campaign-with-ankle-bracelet-from-mar-a-lago-as-former-white-house">Trump May Campaign With Ankle Bracelet From Mar-A-Lago, Former White House Aide Points Out Ex-President&#8217;s &#8216;Cardinal Sin&#8217;</a></em></p>
<p><strong>Why It Matters</strong>: Trump is not among those charged in Arizona. The indictment documents suggest he is "Unindicted Coconspirator 1."</p>
<p>"In Arizona, and the United States, the people elected Joseph Biden as President on November 3, 2020," the indictment <a href="https://www.washingtonpost.com/documents/60db1a4f-b6a8-4973-9b3c-6aefb53ac5e8.pdf?itid=lk_inline_manual_5">reads.</a> </p>
<p>"Unwilling to accept this fact, Defendants and unindicted co-conspirators schemed to prevent the lawful transfer of the presidency to keep Unindicted Coconspirator 1 in office against the will of Arizona's voters.</p>
<p>Among those charged:</p>
<ul>
<li><strong>Mark Meadows</strong>, Trump's former White House chief of staff </li>
<li><strong>Boris Epshteyn</strong>, a longtime Trump aide who was charged with conspiracy, fraud and forgery</li>
<li><strong>Christina Bobb</strong>, once touted as the GOP&#8217;s "election integrity" lawyer, was indicted for election subversion</li>
<li><strong>Mike Roman</strong>, a former Trump campaign aide who oversaw Election Day operations </li>
<li><strong>Jenna Ellis</strong>, another Trump lawyer, who already pleaded guilty in Georgia for trying to subvert the 2020 election</li>
</ul>
<p>Several of Trump&#8217;s pals have already been sentenced for charges separate from election fraud:</p>
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/02/37054850/pro-trump-propaganda-in-focus-steven-bannon-continues-to-spread-disinformation-despite-facing-ma">Former Trump advisors</a> <strong>Steve Bannon</strong> and <strong>Peter Navarro</strong> — both in contempt of Congress for defying a subpoena from the Jan. 6 select committee. </li>
<li><strong>Michael Cohen</strong>, who is testifying against Trump as part of the hush money and falsified business record <a href="https://www.benzinga.com/news/24/05/38844560/michael-cohen-remarkably-good-at-ny-hush-money-trial-says-ex-doj-attorney-slams-defenses-beyond-thin">trial in New York</a>.</li>
<li>Trump&#8217;s former campaign chair <strong>Paul Manafort</strong> was <a href="https://www.benzinga.com/government/19/03/13353619/manafort-sentenced-to-43-more-months-of-prison-time-indicted-on-new-crimin">sentenced to 7 1/2 years in prison</a> for fraud related to his work in Ukraine.</li>
<li><strong>George Papadopoulos</strong>, a former Trump campaign advisor, served 12 days in prison in 2018 for lying to investigators about Russian contacts. Trump pardoned him in December 2020.</li>
<li><strong>Roger Stone</strong>, a Trump associate, was sentenced to more than three years in prison in 2020 for witness tampering. Trump commuted Stone&#8217;s sentence, and the two have on occasion <a href="https://www.benzinga.com/news/23/07/33155927/trump-ally-roger-stone-joins-ex-president-on-flight-to-las-vegas-after-iowa-campaign-stop">been campaigning together</a>.</li>
<li><strong>Rick Gates</strong>, Trump&#8217;s deputy chairman for the 2016 campaign, spent 45 days in prison <a href="https://www.benzinga.com/news/17/10/10247034/paul-manafort-rick-gates-indicted">for lying to the FBI</a>. </li>
</ul>
<p><strong>What&#8217;s Next</strong>: The summons — formal notice that Giuliani has been criminally charged — states he must appear before a judge on May 21.</p>
<p>Whether <a href="https://www.benzinga.com/government/21/01/19152983/donald-trump-is-the-first-us-president-to-be-impeached-twice">twice-impeached</a> Trump will continue helping Giuliani with legal costs&nbsp;<a href="https://www.benzinga.com/news/23/08/33888343/reluctant-trump-asked-by-giuliani-to-foot-legal-bill-at-mar-a-lago-meeting" target="_blank" rel="noreferrer noopener">remains to be seen</a>. Their relationship has been reportedly&nbsp;<a href="https://www.benzinga.com/news/23/09/34188899/trump-unhappy-with-giuliani-for-not-winning-cases-biographer-says-relationship-hasnt-gone-to-where-i" target="_blank" rel="noreferrer noopener">strained largely due</a> to Giuliani's unsuccessful legal battles on Trump's behalf.</p>
<p><em>Now Read: <a href="https://www.benzinga.com/general/politics/24/05/38849634/biden-signals-intent-to-debate-trump-in-june-make-my-day-pal">Biden Signals Intent To Debate Trump In June — &#8216;Make My Day, Pal&#8217;</a></em></p>
<p><em>Image: Shutterstock</em>.</p>


Politics

Where On Earth Is Rudy Giuliani? Arizona Prosecutors Can't Find Former NYC Mayor, Trump Ally

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>For cannabis stock investors, April ended in absolute euphoria. The sector has skyrocketed this week.</p>



<p>The rally came on reports that the U.S. Drug Enforcement Agency (<span>DEA</span>) is set to <a href="https://apnews.com/article/marijuana-biden-dea-criminal-justice-pot-f833a8dae6ceb31a8658a5d65832a3b8">reclassify marijuana&rsquo;s</a> controlled substance status. Marijuana is currently in Schedule 1, which is the strictest level of regulatory enforcement. This planned reclassification would move marijuana from Schedule 1, alongside drugs like LSD, to Schedule 3, where less serious drugs such as ketamine and anabolic steroids reside.</p>



<p>While this wouldn&rsquo;t amount to total federal legalization, it&rsquo;d be a strong step in the right direction for the cannabis industry. This would ease various restrictions and red tape around things such as banking and payments acceptance for U.S. cannabis companies today.</p>



<p>Traders seem to have taken a buy the whole industry approach, indiscriminately bidding up a huge number of pot stocks on the news. However, not all <a href="https://investorplace.com/industries/healthcare/cannabis/">marijuana stocks</a> will benefit equally. These three marijuana stocks to avoid are still in deep trouble, regardless of the recent regulatory news.</p>



<h2>Canopy Growth (CGC)<span><a href="https://investorplace.com/stock-quotes/-stock-quote/"></a></span></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/cgc-1600-1-300x169.png" alt="Closeup of mobile phone screen with logo lettering of cannabinoid company canopy growth cannabis, blurred marijuana in the background. CGC stock."><div>Source: Ralf Liebhold / Shutterstock</div></div><p><strong>Canopy Growth</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cgc-stock-quote/"><strong>CGC</strong></a></span>) is one of the longer-running publicly traded cannabis stocks. Shares skyrocketed in 2018 as investors warmed up to a potential boom in the Canadian cannabis market.</p>



<p>Since that point, however, CGC stock has been an utter trainwreck. Shares have fallen from a (split-adjusted) peak of around $500 per share in 2018 to less than $15 today. The company has engaged in an unceasing string of dilution to fund its massively loss-generating operations. Last quarter alone, the company lost <a href="https://www.canopygrowth.com/wp-content/uploads/2024/02/Canopy-Growth-Reports-Third-Quarter-Fiscal-2024-Financial-Results.pdf">$230 million</a> Canadian dollars from operations.</p>



<p>Simply put, the legal Canadian cannabis market never took off to nearly the degree that investors had been banking on. At the same time, entrepreneurs treated the sector as a gold mine, and way too much capital went flooding into the Canadian recreational market leading to a massive <a href="https://www.bbc.com/news/world-us-canada-67126243">supply/demand imbalance</a>.</p>



<p>Despite Canopy&rsquo;s long track record of unsuccessful operations, traders have given the company yet another chance. Shares have now more than doubled year-to-date following this week&rsquo;s rally.</p>



<p>However, the company is far more tied to the Canadian than American market making this reclassification catalyst of dubious value to Canopy specifically. Given Canopy&rsquo;s large operating losses and substantial debtload, more share dilution and a slumping stock price seem likely going forward, despite the recent excitement.</p>



<h2>Aurora Cannabis (ACB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/acb_auroracannabis1600-300x169.png" alt="Closeup of mobile phone screen with logo lettering of cannabinoid company Aurora Cannabis (ACB, blurred marijuana leaf (focus on left part of letter R in center)"><div>Source: Ralf Liebhold / Shutterstock.com</div></div><p>With more than 1,100 employees, <strong>Aurora Cannabis</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/acb-stock-quote/"><strong>ACB</strong></a></span>) is one of the larger companies in the cannabis space. The company has attempted to take a conglomerate approach to the industry, launching a wide variety of operations. Its main divisions are Canadian cannabis, European cannabis, and plant propagation.</p>



<p>The firm has searched far and wide for growth opportunities, going so far as to distribute wholesale medicinal cannabis in markets as far away as Australia, Israel and South America.</p>



<p>For all the company&rsquo;s efforts, however, it doesn&rsquo;t have much to show for it. The company generated $198 million of revenues in fiscal year 2020, but the figure fell to $173 million in fiscal year 2023. Simply put, there&rsquo;s been a massive glut in the cannabis market, pressuring pricing and causing large quantities of inventory pile-up for leading Canadian distributors.</p>



<p>Analysts are hopeful that Aurora will finally return to revenue growth in 2024. Even so, analysts expect the company to keep <a href="https://seekingalpha.com/symbol/ACB/earnings/estimates">losing money</a> for the next two years. Given the high level of competition and low profit margins in the industry, ACB stock will have &mdash; at best &mdash; an uphill climb over the next few years.</p>



<p>Like with Canopy, Aurora shares leapt this week even though Aurora seems unlikely to benefit much even if the U.S. regulatory environment improves.</p>



<h2>Flora Growth (FLGC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/01/marijuana1600e-300x169.jpg" alt="Marijuana plants growing in a greenhouse."><div>Source: Shutterstock</div></div><p><strong>Flora Growth</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/flgc-stock-quote/"><strong>FLGC</strong></a></span>) is a small cannabis company attempting to commercialize marijuana cultivation operations in the nation of Colombia.</p>



<p>In theory, this would make for an attractive business model. Thanks to Colombia&rsquo;s warm climate and cheap cost of labor, it should be much more economical to produce cannabis in Colombia than in cold weather countries such as Canada. Colombia has a successful export industry for <a href="https://www.floraldaily.com/article/9567195/colombian-flower-industry-in-numbers/">cut flowers</a> and tropical fruits, so it was natural to think cannabis could follow a similar trajectory.<span><a href="https://investorplace.com/stock-quotes/-stock-quote/"></a></span></p>



<p>However, regulatory matters make it more complicated than that. Not surprisingly, there is a great deal of red tape in moving cannabis across international boundaries. Both Flora and fellow Colombian cannabis company <strong>Clever Leaves</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/clvr-stock-quote/"><strong>CLVR</strong></a></span>) have seen their shares <a href="https://finance.yahoo.com/news/clever-leaves-announces-voluntary-delisting-201000112.html">utterly implode</a> over the past two years.</p>



<p>That share price beating is well-deserved. In the case of Flora Growth, it managed to lose $54 million over the past 12 months on revenues of $77 million over the same period. Companies tend to not remain in business for long with those sorts of profitability metrics.</p>



<p>In addition to Flora&rsquo;s operational problems, short sellers have also raised concerns about Flora. A scathing 2021 <a href="https://whitediamondresearch.com/research/flora-growth-a-cannabis-company-of-deception-unprofessionalism-and-stock-pump-and-dumps-2-price-target/">short seller report</a> noted that Flora acquired its key operating asset in Colombia for a mere $80,000 consideration. The report also highlighted concerns about insiders and the management team at the company.</p>



<p>FLGC stock has collapsed in value since that report &mdash; and given the concerns raised and the company&rsquo;s subsequently sour operational results, it&rsquo;s worth wondering whether Flora will have any terminal value at all.</p>



<p><em>On the date of publication, Ian Bezek did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<div><p>Ian Bezek has written more than 1,000 articles for InvestorPlace.com and Seeking Alpha. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. You can reach him on Twitter at @irbezek.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/stock-market-crash-warning-dont-get-caught-holding-these-3-cannabis-stocks/">Stock Market Crash Warning: Don&#8217;t Get Caught Holding These 3 Cannabis Stocks</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Stock Market Crash Warning: Don't Get Caught Holding These 3 Cannabis Stocks

The cannabis sector dropped 18.8% in the last 3 days and it probably has further to go, based on historical data.so the question now is how much further it will drop before stabilizing. Time will tell. Stay tuned. 

Cannabis Stocks Dropped 19%, On Average, In Last 3 Days Of This Week

BTIG sees "murky" road ahead for cannabis reclassification

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Multiple <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> to buy should climb higher thanks to Washington&rsquo;s efforts to help the sector. So far, the federal government looks poised to undertake two initiatives that should greatly boost marijuana companies in the long term. First, Congress <a href="https://cei.org/blog/how-safer-banking-act-poses-new-dangers-to-marijuana-and-other-legal-industries/#:~:text=And%20on%20Capitol%20Hill%2C%20there,businesses%20operating%20in%20states%20that">appears to be poised to pass the </a>SAFER Banking Act this year. The bill would explicitly authorize banks to provide loans and other financial services to cannabis companies. Of course, American marijuana distributers would be able to expand more readily if they had easier access to U.S. banking loans. Importantly, SAFER <a href="https://www.americanbar.org/groups/business_law/resources/business-law-today/2024-february/safer-banking-act/">was already passed by the</a> Senate Banking Committee by a 14-9 count, suggesting a high chance of the bill becoming law.</p>



<p>Secondly, the&nbsp;Drug Enforcement Administration will reportedly lessen cannabis restrictions. The <a href="https://www.nbcnews.com/politics/joe-biden/biden-administration-plans-reclassify-marijuana-easing-restrictions-na-rcna149424">change would enable</a>&nbsp;pharmaceutical companies to sell and distribute medical marijuana in legal states. This should boost cannabis&rsquo; firms top and bottom lines. For investors who want to benefit from Washington&rsquo;s move, here are three cannabis stocks to buy.</p>



<h2>Aurora Cannabis (<strong>ACB</strong>)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/acb_auroracannabis1600-300x169.png" alt="Closeup of mobile phone screen with logo lettering of cannabinoid company Aurora Cannabis (ACB, blurred marijuana leaf (focus on left part of letter R in center)"><div>Source: Ralf Liebhold / Shutterstock.com</div></div><p><strong>Aurora Cannabis </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/acb-stock-quote/"><strong>ACB</strong></a></span>) reportedly <a href="https://www.fool.com/investing/2023/10/01/3-things-about-aurora-cannabis-that-smart-investor/">doesn&rsquo;t have an official presence in the U.S.</a> But the company should still be able to generate a great deal of revenue and profits by selling the marijuana that it grows in Canada to U.S. pharmaceutical firms.</p>



<p>What&rsquo;s more, Aurora Cannabis is very well-positioned to benefit from Germany&rsquo;s recent legalization of marijuana. That&rsquo;s because Aurora is one of only three firms<a href="https://investorplace.com/2024/04/cashing-in-on-cannabis-why-these-3-weed-stocks-are-primed-to-pop/"> that can grow marijuana </a>in the European country.</p>



<p>Aurora&rsquo;s revenue rose 5.4% in its fiscal third quarter to 64.4 million Canadian dollars. Meanwhile its EBITDA came in at 4.3 million Canadian dollars, up from 3 million Canadian dollars during the same period a year earlier.</p>



<h2>Canopy Growth (<strong>CGC</strong>)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/Canopy-Growth-Stock_0509-300x169.jpg" alt="The More CGC Stock Flounders, the Less Constellation Can Handle It"><div>Source: Shutterstock</div></div><p><strong>Canopy Growth </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cgc-stock-quote/"><strong>CGC</strong></a></span>)<a href="https://seekingalpha.com/news/4089545-canopy-growth-to-expedite-entry-into-us-cannabis-market"> is taking steps to launch</a> a new U.S.-based holding company that will acquire multiple firms within the American cannabis market. As a result, Canopy will be exceptionally well-positioned to benefit from the SAFER Banking Act and the government&rsquo;s relaxation of restrictions on cannabis. Consequently, Cannabis is certainly one of the best cannabis stocks to buy. </p>



<p>In Canopy&rsquo;s Q3, its revenue<a href="https://seekingalpha.com/pr/19619133-canopy-growth-reports-third-quarter-fiscal-year-2024-financial-results-achieves-third-quarter?hasComeFromMpArticle=false"> climbed 6% versus the same period</a> a year earlier. Even more impressively, the revenue that it generated from cannabis outside of its Canadian home market soared 81% YOY to $10.5 million.</p>



<p>The firm&rsquo;s <a href="https://finance.yahoo.com/quote/CGC/key-statistics">price/sales ratio of 2.5 times </a>is very attractive, given its huge, upcoming opportunities.</p>



<h2>Tilray (TLRY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/tlry_tilray1600-2-300x169.png" alt="Close view of Tilray (TLRY) logo on a smart phone. Tilray specializes in cannabis research, cultivation, processing and distribution. TLRY stock. cannabis stocks to buy"><div>Source: Lori Butcher / Shutterstock.com</div></div><p>In a statement to <em>Barron&rsquo;s</em>, <strong>Tilray</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tlry-stock-quote/"><strong>TLRY</strong></a></span>) CEO Irwin Simon <a href="https://www.barrons.com/articles/marijuana-reclassification-tilray-stock-canopy-63a025c1">wrote that</a> Washington&rsquo;s relaxation of restrictions on cannabis &ldquo;paves the way for the establishment of a federally legal medical cannabis industry.&rdquo; Simon added that &ldquo;&ldquo;We believe that we are well-positioned and ready to participate in the medical cannabis market in the U.S.&rdquo;</p>



<p>Indeed, Tilray is one one of the largest medical cannabis businesses in both Canada and Europe. Its expertise in medical marijuana should cause it to benefit from the growth of the U.S. medical marijuana sector. The Biden administration&rsquo;s reduced cannabis restrictions will enable drug companies to start selling cannabis for use by medical patients. As a result, drug companies will use their huge marketing power to promote medical marijuana, benefiting Tilray.</p>



<p>The<a href="https://finance.yahoo.com/quote/TLRY/key-statistics"> price/book ratio of Tilray</a> is a tiny 0.50.</p>



<p><em>On the date of publication, Larry Ramer held a long position in ACB. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a></em>.</p>
<div><p>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel&rsquo;s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/cashing-in-on-cannabis-3-stocks-primed-to-surge-on-federal-reforms/">Cashing In on Cannabis: 3 Stocks Primed to Surge on Federal Reforms</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Cashing In on Cannabis: 3 Stocks Primed to Surge on Federal Reforms

Aurora Cannabis (US) (TSE:ACB) has released an update. Aurora Cannabis Inc., a leading Canadian medical cannabis company, has made its first shipme...

Aurora Cannabis Expands to New Zealand Market

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> to buy for investments in May.</p>



<p>Although the results so far from the cannabis industry have disappointed many investors, I feel that the long-term prospects remain promising. While the initial hype and optimism surrounding the legalization of cannabis may have led to unrealistic expectations, it is important to recognize that this industry is still in its infancy, and its true potential has yet to be fully realized.</p>



<p>The current disappointment can be attributed to several factors, including regulatory hurdles, supply chain challenges, and intense competition within the market, still the overall growth and trajectory of the market remains positive.</p>



<p>So here are seven cannabis stocks to buy for investors to consider for May this year.</p>



<h2>Canopy Growth (CGC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cgc1600-300x169.png" alt="Person holding cellphone with business logo of Canadian cannabis company Canopy Growth Corp. (CGC) on screen in front of webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p>Established in 2009, <strong>Canopy Growth</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/cgc-stock-quote/"><strong>CGC</strong></a>) was the first cannabis company to trade on the <strong>NYSE</strong>.&nbsp;</p>



<p>In fiscal year 2023, <a href="https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-second-quarter-fiscal-year-2024-financial-results/">CGC faced several challenges</a>. The company reported a net revenue decline of 21% year-over-year, amounting to $403 million. This downturn was primarily due to increased competition in the Canadian adult-use cannabis market and the divestiture of certain business units.<br><br>Looking forward to this year, however, CGC is focusing on a few strategic areas to drive growth. The company aims to enhance its financial standing by targeting an &ldquo;asset light&rdquo; business model, which includes reducing its cost of goods sold (COGS) and selling, general, and administrative expenses (SG&amp;A) by $270 to $300 million in total. Innovations are on the horizon for its product lines. For instance, <strong>Storz &amp; Bickel</strong> is anticipated to launch new vaporizers in FY2024, which are expected to contribute to revenue growth.</p>



<p>CGC&rsquo;s valuation could be too cheap for investors to ignore, which makes it one of those cannabis stocks to buy.</p>



<h2>Aurora Cannabis (ACB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/acb_auroracannabis1600-300x169.png" alt="Closeup of mobile phone screen with logo lettering of cannabinoid company Aurora Cannabis (ACB, blurred marijuana leaf (focus on left part of letter R in center)"><div>Source: Ralf Liebhold / Shutterstock.com</div></div><p><strong>Aurora Cannabis</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/acb-stock-quote/"><strong>ACB</strong></a>) has a strong presence in over 25 countries. Known for its medicinal cannabis production.</p>



<p>ACB is focusing on <a href="https://www.nasdaq.com/press-release/aurora-cannabis-announces-fiscal-2024-second-quarter-results-and-delivers-record">stabilizing and growing revenue</a> across various segments. The company expects steady revenue from Canadian medical and consumer segments and anticipates modest growth in Europe and Australia.</p>



<p>Analysts maintain a &ldquo;Hold&rdquo; rating with price targets suggesting a potential moderate increase in stock price. The estimated price targets reflect an upward potential of 18.59% to 48.24%.</p>



<p>However, ACB&rsquo;s forecast for its EPS is strong. It&rsquo;s expected to reach a positive number sometime around FY2025, with it reaching a triple-digit growth rate in FY2026. I think then it could be a good way to enter the market, especially if one is bullish on the medicinal cannabis segment.</p>



<p>It should be noted that these EPS growth projections also come with top-line revenue increases as well, which could further bolster its valuation.</p>



<h2>Tilray (TLRY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/tlry_tilray1600-300x169.png" alt="Mobile phone with webpage of Canadian cannabis company Tilray (TLRY) Inc. on screen in front of business logo. Focus on top-left of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Tilray</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlry-stock-quote/"><strong>TLRY</strong></a>) merged with <strong>Aphria</strong> in 2020, becoming one of the largest cannabis companies globally.&nbsp;</p>



<p>Tilray is <a href="https://www.nasdaq.com/press-release/tilray-brands-delivers-record-q2-fiscal-2024-net-revenue-2024-01-09">poised for continued growth</a> in 2024. Key strategies include optimizing its brand portfolio and expanding distribution networks in the U.S., Canada, and Europe. Additionally, Tilray is focused on increasing its medical cannabis market share internationally.</p>



<p>The reason I like TLRY is that it has managed to pull off what many cannabis stocks have struggled with in the past. It has successfully reduced its debt significantly, enhancing its financial flexibility. The company also achieved considerable operational synergies and cost savings from recent acquisitions, which are expected to contribute to further financial stability and growth.</p>



<p>Notably, the company achieved record net revenues in multiple quarters, with a marked increase in the fiscal third quarter of 2024 compared to the previous year. This growth was supported by strong sales in Canadian cannabis operations.</p>



<h2>Leafly Holdings (LFLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/cannabis-stocks1600-300x169.png" alt="Marijuana Cannabis Leaf Stock Market Symbol Company Business 3d Illustration. Cannabis stocks"><div>Source: iQoncept / Shutterstock.com</div></div><p><strong>Leafly Holdings</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lfly-stock-quote/"><strong>LFLY</strong></a>) focuses on the recreational cannabis market. Despite its smaller market cap, it&rsquo;s recognized for its influential role in cannabis cultivation and production.</p>



<p>For the first quarter of 2024, <a href="https://greenstocknews.com/news/nasdaq/lfly/leafly-holdings-inc-reports-fourth-quarter-and-full-year-2023-financial-results">Leafly forecasts revenue</a> around $9 million and anticipates an adjusted EBITDA loss of approximately $1 million. The company is focused on overhauling its revenue operations and enhancing its sales structure.</p>



<p>Last year, LFLY&rsquo;s average revenue per account (ARPA) increased by 21%, indicating a shift towards higher-value accounts. The company ended the year with $15.3 million in cash and is prioritizing addressing its liquidity issues as it faces $29.7 million in convertible notes due in 2025&#8203;.</p>



<p>LFLY trades at just $2.93 per share, and its stock price has fallen 64.44% over the past year alone. Due to its capital and debt structure, LFLY could be seen as risky and speculative, but it may make up for iit through offering a stronger implied upside.</p>



<h2>Jazz Pharmaceuticals (JAZZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/jazz-stock-1-300x169.jpg" alt="Image of the Jazz Pharmaceuticals logo on a sign"><div>Source: Michael Vi / Shutterstock.com</div></div><p><strong>Jazz Pharmaceuticals </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/jazz-stock-quote/"><strong>JAZZ</strong></a>) became a notable player in the cannabis pharmaceutical sector by acquiring <strong>GW Pharmaceuticals</strong> in 2021, maker of the FDA-approved, cannabis-based drug Epidiolex, for the treatment of epilepsy.</p>



<p>JAZZ reported strong financial results in 2023, with total revenues reaching $3.8 billion, a 27% year-over-year increase.</p>



<p>The company is now focusing on <a href="https://stockanalysis.com/stocks/jazz/">expanding its neuroscience</a> and oncology portfolios, including advancing late-stage clinical trials and new drug applications. Jazz&rsquo;s strategic priorities include further integration of GW Pharmaceuticals&rsquo; capabilities, especially in cannabinoid-based treatments.</p>



<p>The reason I like JAZZ is that the company is pursuing a number of diversified pipelines, as opposed to putting all of its eggs in one basket. This could then reduce risk, and also give investors exposure to the pharmaceutical industry as well as having a strong presence in the cannabis sector.&nbsp;</p>



<h2>Curaleaf Holdings (CURLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/cannabis-stocks1600-1-300x169.png" alt="Business cannabis leaves marijuana stock exchange market or trading analysis investment indicator graph charts. The concept of a company or stock market of marijuana exports for medical use. Cannabis stocks"><div>Source: C.Aphirak / Shutterstock.com</div></div><p><strong>Curaleaf Holdings</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/curlf-stock-quote/"><strong>CURLF</strong></a>) leads in the industry in the U.S. and Europe. Despite not trading on a major U.S. exchange, its size and scope make it a significant entity for investors to pay attention to.<br><br>The company&rsquo;s <a href="https://ir.curaleaf.com/">revenue for the fourth quarter</a> was reported at $345.27 million, exceeding analyst expectations. Over the year, Curaleaf successfully expanded its market presence, including rebranding initiatives in Arizona and the UK, and acquiring a pharmaceutical wholesaler in Poland.</p>



<p>The reason I like CURLF is its recent acquisition of <strong>Northern Green Canada</strong> is a strategic move to bolster its position in key emerging markets, including Australia, New Zealand, Germany,&nbsp; and boland. This expansion aligns with its goal to be a global leader in the cannabis industry.</p>



<p>Also, despite being an OTC stock, CURL is one of the largest companies in the U.S. market via market cap and revenue, which means it has a commanding share of the market.</p>



<h2>Cronos Group (CRON)</h2>



<a href="https://investorplace.com/wp-content/uploads/2019/06/cron1.jpg"><img width="300" height="225" src="https://investorplace.com/wp-content/uploads/2019/06/cron1-300x225.jpg" alt="Even Contrarian Investors Should Hold off on CRON Stock for Now"></a><p><strong>Cronos Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cron-stock-quote/"><strong>CRON</strong></a>) <a href="https://stockhouse.com/news/press-releases/2024/02/29/cronos-group-reports-2023-fourth-quarter-and-full-year-results-xb9">made notable progress</a> in 2023, achieving a significant improvement in its financial health. The company managed to reduce its adjusted EBITDA loss by $8.7 million compared to the previous year, primarily through reductions in general and administrative and research and development expenses. This was part of a broader initiative to cut operating expenses, which exceeded its target, achieving $30 million in savings&#8203;.</p>



<p>The company plans to save an additional $5 to $10 million in operating expenses. These savings are expected to come mainly from general and administrative and research and development costs. Cronos Group also expects positive net changes in cash for the year.</p>



<p>CRON also continues to strengthen its brand portfolio, particularly with its <strong>Spinach</strong> brand in Canada, which has seen significant growth across various cannabis product categories. Spinach now holds a leading position in the edibles market and is growing in other categories like flowers, vapes, and pre-rolls.</p>



<p>CRON is therefore showing strong promise in the edibles sector of the industry, which makes it one of those cannabis stocks for investors to consider.</p>



<p><em>On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> </em>InvestorPlace.com Publishing Guidelines</a>.</p>
<div><p>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-cannabis-stocks-to-buy-for-a-smoking-hot-2024/">7 Cannabis Stocks to Buy for a Smoking-Hot 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Cannabis Stocks to Buy for a Smoking-Hot 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><a href="https://investorplace.com/industries/healthcare/cannabis/">Cannabis stocks</a> are back in the spotlight and moving higher on news that the U.S. government is moving to reclassify the recreational drug and ease federal restrictions imposed on it. </p>



<p>The Biden administration has taken steps to reclassify cannabis, also known as marijuana, as <a href="https://apnews.com/article/marijuana-reclassification-biden-garland-dea-3c9478472e124c7aaa9b934270b0d450">a Schedule III substance</a>. For more than 50 years, cannabis has been labeled as a Schedule I substance in America, the same category as hard drugs such as heroin and acid.</p>



<p>A move to Schedule III status would place cannabis alongside <a href="https://www.nbcnews.com/politics/joe-biden/biden-administration-plans-reclassify-marijuana-easing-restrictions-na-rcna149424">less harmful drugs </a>and prescription medications such as Tylenol with codeine in it. News of the reclassification is being seen as a potential lifeline for cannabis companies and their shareholders. </p>



<p>Legalization of cannabis at the national level in America has long been seen as critical to the growth of the cannabis industry, and the reclassification is a big step forward in that direction.</p>



<p>With the reclassification of cannabis top of mind, here are the three best cannabis stocks to buy in May 2024.  </p>



<h2>Tilray Brands (TLRY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/tlry1600-300x169.png" alt="In this photo illustration, the Tilray Brands (TLRY) logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div><p>Like most cannabis producers, <strong>Tilray Brands</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tlry-stock-quote/"><strong>TLRY</strong></a></span>) is struggling. The company recently reported <a href="https://www.barrons.com/articles/tilray-earnings-stock-price-marijuana-063c4801">a quarterly loss </a>of $105 million and lowered its forward guidance as its sales continue to struggle. The company said that it lost 12 cents per share for its fiscal third quarter ended Feb. 29. Revenue totalled $188.3 million. </p>



<p>The results were better than a loss of $1.20 billion and revenue of $145.6 million recorded a year earlier. But not good enough to keep TLRY stock aloft.</p>



<p>In the last 12 months, TLRY stock has declined 28%, including a 11% drop so far in 2024. Over the last five years, the <a href="https://www.investopedia.com/tilray-stock-tanks-following-earnings-miss-outlook-cut-8628796">share price has fallen 96%</a> and now trades as a penny stock. </p>



<p>Things have worsened for Tilray since the company said that it expects earnings of only $60 million this fiscal year. While the current situation is not great, Tilray is in a good position to capitalize on any relaxation in U.S. cannabis laws. The company has <a href="https://www.greenmarketreport.com/ex-tilray-exec-battles-to-keep-4m-win-company-cries-foul/">relocated</a> its headquarters to New York City from Toronto as it focuses on the American market.</p>



<h2>Canopy Growth (CGC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/Canopy-Growth-Stock_0509-300x169.jpg" alt="The More CGC Stock Flounders, the Less Constellation Can Handle It"><div>Source: Shutterstock</div></div><p><strong>Canopy Growth</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cgc-stock-quote/"><strong>CGC</strong></a></span>) is struggling mightily but remains one of the bigger cannabis producers. The company has long said that <a href="https://www.forbes.com/sites/javierhasse/2024/05/07/canopy-growth-executives-share-master-plan-to-dominate-us-cannabis/?sh=418d09c64bc3">legalization in the U.S.</a> is key to its future. As such, a reclassification decision couldn&rsquo;t come soon enough for Canopy Growth.</p>



<p>The company most recently reported a <a href="https://www.bnnbloomberg.ca/cannabis-company-canopy-growth-reports-216-8m-q3-net-loss-1.2033114#:~:text=Canopy%20Growth%20Corp.%20reported%20a,for%20the%20quarter%20ended%20Dec.">net loss</a> of $216.8 million. Canopy Growth says the loss equated to $2.62 per share. Revenue for what was the company&rsquo;s fiscal third quarter totalled $78.5 million, down 8% from a year earlier.</p>



<p>Earlier this year, Canopy Growth undertook <a href="https://www.baystreet.ca/stockstowatch/16668/Canopy-Growths-Stock-Falls-20-On-News-Of-Reverse-Stock-Split">a reverse stock split</a> to boost its share price, which is down 98% over the last five years. The company continues to struggle with declining sales and a loss of market share in its native Canada, even as it awaits a breakthrough in America. </p>



<p>In recent months, the company has sold its corporate headquarters and placed part of its business under creditor protection. However, news of the U.S. reclassification sent CGC stock up 80% in one trading day.</p>



<h2>Aurora Cannabis (ACB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/acb_auroracannabis1600-300x169.png" alt="Closeup of mobile phone screen with logo lettering of cannabinoid company Aurora Cannabis (ACB, blurred marijuana leaf (focus on left part of letter R in center)"><div>Source: Ralf Liebhold / Shutterstock.com</div></div><p><strong>Aurora Cannabis</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/acb-stock-quote/"><strong>ACB</strong></a></span>) is another company that was forced to undertake a <a href="https://globalnews.ca/news/10262315/aurora-cannabis-to-consolidate-shares/">reverse stock split </a>this year to prop up its share price, which has fallen 99% since 2019. </p>



<p>Like the other names in this article, Aurora Cannabis is trying to hold on while it awaits significant policy change at the federal level in America. In the meantime, the company has tried to boost sales by focusing on medical cannabis and targeting <a href="https://www.prnewswire.com/news-releases/aurora-marks-first-shipment-of-medical-cannabis-to-the-new-zealand-market-302139357.html">overseas markets</a> such as Germany and New Zealand.</p>



<p>Things are starting to <a href="https://ca.finance.yahoo.com/news/aurora-cannabis-acb-moves-46-062700692.html">look more positive</a> for Aurora Cannabis. For its next earnings report, analysts forecast that the company will report a quarterly loss of 18 cents per share, which would represent a year-over-year change of positive 88%. </p>



<p>Revenues are expected to be $52.11 million, up 10% from a year ago. While ACB stock is likely not out of danger just yet, reclassification and movement towards eventual legalization in America should help the company and its shareholders moving forward.</p>



<p><em>On the date of publication, Joel Baglole did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the <em>InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></em></p>
<div><p>Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/the-3-best-cannabis-stocks-to-buy-in-may-2024/">The 3 Best Cannabis Stocks to Buy in May 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Best Cannabis Stocks to Buy in May 2024

It appears to be déjà vu all over again! The Canadian Cannabis LPs Portfolio has dropped by 30.5% since April 30th as a result of the 6.9% decline in the Portfolio last week. This article provides stock performances last week by constituent:

Canadian Cannabis LPs Portfolio Went Down 7% Last Week

Aurora Cannabis (US) (TSE:ACB) has released an update. Aurora Cannabis Inc., a Canadian leader in global medical cannabis, has made its first shipm...

Aurora Cannabis Enters New Zealand Market

Aurora Cannabis (US) (TSE:ACB) has released an update. Aurora Cannabis has announced the strategic appointment of Rajesh Uttamchandani to its Board...